Camp4 Therapeutics annual return on equity
2025
Camp4 Therapeutics Return on Equity (ROE) Growth & History (CAMP)
Camp4 Therapeutics's return on equity was −145.07% for fiscal 2025.
View full Camp4 Therapeutics company overviewCamp4 Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −145.07% | — |
Camp4 Therapeutics quarterly return on equity
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −221.99% | −194.49 pp |
| Q1 2026 | 2026-03-31 | −46.64% | −24.96 pp |
| Q4 2025 | 2025-12-31 | −75.74% | — |
| Q3 2025 | 2025-09-30 | −30.61% | — |
| Q2 2025 | 2025-06-30 | −27.49% | — |
| Q1 2025 | 2025-03-31 | −21.68% | — |
Camp4 Therapeutics return on equity trends
The latest reported quarter, Q2 2026, shows −221.99%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Camp4 Therapeutics source filings ↗Community posts
CAMP4 receives UK authorization for its first SYNGAP1 clinical study
CAMP4 Therapeutics ($CAMP) received UK authorization to include sites in its global Phase 1/2 study of CMP002, an investigational treatment for SYNGAP1-related disorder. The decision follows earlier clearances in Australia and Argentina, wh ...